The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non‐segmental vitiligo
Journal of Cosmetic Dermatology · 2023-03 · 22 (3) · 1105-1107
DOI: 10.1111/jocd.15537 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 28.11.2022. Verfasst von Faraz Yousefian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical and Cosmetic Research, Aventura, Florida, USA. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Vitiligo, Ultraviolet Therapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Vitiligo is a depigmentation disorder of the skin that occurs secondary to the destruction of melanocytes by an immune‐mediated process. Vitiligo clinically presents with depigmented macules and patches, most commonly on the face, acral sites, and genitalia. It can be characterized as generalized or localized based on distribution. The localized form can be further divided into segmental (linear, band‐like, or Blaschkoid) and non‐segmental vitiligo. The classical treatment of vitiligo includes topical steroids, pulsed oral steroids in unstable vitiligo, phototherapy, a combination of steroid therapy and phototherapy, surgical grafting, as well as intentional depigmentation therapy in severe cases. However, recent advances in understanding the immune mechanisms implicated in the pathogenesis of vitiligo have led to the use of an FDA‐approved topical Janus kinase (JAK) inhibitors for vitiligo. Despite this novel therapy advancement, we recommend the addition of narrowband ultraviolet B (NB‐UVB) to JAK inhibitors in patients with extensive and progressive lesions, or those not fully responsive to JAK inhibitor monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical and Cosmetic Research, Aventura, Florida, USA.
- HCA Corpus Christi Medical Center- Bay Area Dermatology Residency Program, McAllen, Texas, USA.
- Adjunct Associate Professor, UT Health San Antonio Medical Director, Texas Dermatology and Laser Specialists, San Antonio, Texas, USA.
ORCID-Profile: Faraz Yousefian
Zitieren
APA
Yousefian, F., Yadlapati, S., & Browning, J. C. (2023). The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non‐segmental vitiligo. Journal of Cosmetic Dermatology, 22(3), 1105-1107. https://doi.org/10.1111/jocd.15537
Vancouver
Yousefian F, Yadlapati S, Browning JC. The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non‐segmental vitiligo. Journal of Cosmetic Dermatology. 2023;22(3):1105-1107. doi:10.1111/jocd.15537
BibTeX
@article{Yousefian2023,
author = {Yousefian, Faraz and Yadlapati, Sujitha and Browning, John C},
title = {The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non‐segmental vitiligo},
journal = {Journal of Cosmetic Dermatology},
year = {2023},
volume = {22},
number = {3},
pages = {1105--1107},
doi = {10.1111/jocd.15537}
}
EUVIMED